» Articles » PMID: 29608816

Metastasis in Patients with Hepatocellular Carcinoma: Prevalence, Determinants, Prognostic Impact and Ability to Improve the Barcelona Clinic Liver Cancer System

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2018 Apr 3
PMID 29608816
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aim: Patients with hepatocellular carcinoma and metastasis are classified as advanced or terminal stage by the Barcelona Clinic Liver Cancer system. This study investigates the prevalence, determinants, and prognostic effect of metastasis and its ability to improve the Barcelona Clinic Liver Cancer system.

Methods: A total of 3414 patients were enrolled. The Kaplan-Meier and Cox regression methods were used to determine survival predictors. Akaike information criterion was used to compare the prognostic performance of staging systems.

Results: There were 357 (10%) patients having extrahepatic metastasis at the time of diagnosis. Metastases were associated with old age, alcoholism, hepatitis B, poorer liver function, higher α-foetoprotein level and larger tumour burden (all P < .05). Vascular invasion was associated with metastasis regardless of total tumour volume, and higher α-foetoprotein level and multiple tumours were associated with metastasis in patients with smaller tumour volume (all P < .05). Patients with both vascular invasion and metastasis had significantly worse outcome compared to patients with either vascular invasion or metastasis (P < .05). In the Cox proportional model, the co-existence of vascular invasion and metastasis was an independent predictor of decreased survival (P < .05). Re-allocating 181 Barcelona Clinic Liver Cancer stage C patients with both vascular invasion and metastasis into stage D was associated with lower Akaike information criterion, indicating enhanced prognostic power of the Barcelona Clinic Liver Cancer.

Conclusions: Metastasis is not uncommon, and is strongly associated with tumoural factors and poor long-term survival in hepatocellular carcinoma. Modification of the Barcelona Clinic Liver Cancer system based on vascular invasion and metastasis may further improve its predictive accuracy in advanced stage patients.

Citing Articles

Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study.

Liu D, Li Y, Wu J, Zeng Z, Fu Y, Li H J Hepatocell Carcinoma. 2024; 11:2339-2349.

PMID: 39619604 PMC: 11606165. DOI: 10.2147/JHC.S480958.


Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis.

Xu K, Xiang C, Yu Z, Li J, Liu C Immunotargets Ther. 2024; 13:305-317.

PMID: 38910584 PMC: 11192195. DOI: 10.2147/ITT.S458700.


Pretreatment Non-Invasive Biomarkers as Predictors to Estimate Portal Vein Tumor Thrombosis (PVTT) Risk and Long-Term Survival in HBV-Related Hepatocellular Carcinoma Patients Without PVTT.

Liu B, Liu J, Mei X, Zhang Z, Fang J, Zhou L J Hepatocell Carcinoma. 2024; 10:2367-2382.

PMID: 38164511 PMC: 10758161. DOI: 10.2147/JHC.S442487.


Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis.

Wang X, Liu C, Wen H, Duan X, Jiao Y, Liu Y Clin Transl Med. 2023; 13(3):e1214.

PMID: 36855781 PMC: 9975463. DOI: 10.1002/ctm2.1214.


Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.

Xu B, Zhao X, Chen D, Zhao W, Wang X, Ding C BMC Cancer. 2023; 23(1):73.

PMID: 36681809 PMC: 9862519. DOI: 10.1186/s12885-023-10519-9.